
EACH STEP. EVERY PATIENT. EXACTLY WHAT YOU NEED.



A guide to Myriad Oncology testing for Urology

Myriad
Oncology™

From initial treatment guidance to targeted therapy selection, gain actionable genomic answers that empower you to confidently guide every step of the cancer care journey.

Myriad Oncology empowers you to transform prostate cancer patient care

Myriad Oncology offers a suite of services and workflow solutions designed to streamline germline and genomic testing without added cost.



Accurate, useful results

- Accurate, reliable, and actionable results to support informed decisions, typically available within 14 days
- Clear and easy-to-interpret reports for confident clinical direction
- Lifetime commitment to germline variant reclassification



Seamless efficiency

- Solutions for patient identification and bi-directional ordering options
- Provider-defined, customized ordering solutions for the Prolaris Test



Unmatched customer support

- The majority of patients face no out-of-pocket costs for the MyRisk[®] Hereditary Cancer Test¹ and the Prolaris[®] + AI Prostate Cancer Prognostic Test²
- Myriad's Patient Education Program includes pre- and post-test education by board-certified genetic counselors at no additional cost
- Transparent pricing, financial assistance, and other affordability options, including direct pay

Myriad Oncology provides clinical utility across the prostate cancer care continuum



Local Disease

- Active surveillance
- Surgery
- Radiation therapy
- Adjuvant therapy
- Treatment selection

MyRisk[®]
Hereditary Cancer Test

Prolaris[®] + AI
Prostate Cancer Prognostic Test

Late-Stage & Metastatic Disease

- Targeted therapy selection
- Clinical trial eligibility
- Treatment selection

MyRisk[®]
Hereditary Cancer Test

Precise Tumor[®]
Molecular Profile Test

A new level of confidence for managing localized prostate cancer

Prolaris® + AI
Prostate Cancer Prognostic Test

The Prolaris® + AI Test, the **FIRST and ONLY** to unite clinical-pathological features, an independent molecular score, and independent AI-driven digital pathology metric. Together they help guide IF a patient is safe for active surveillance (AS) and HOW intensive the AS protocol should be.³⁻⁸

- **Outperforms all other biomarkers** in identifying the right patients for active surveillance⁹
- In a pivotal study, **no patients below the Prolaris active surveillance threshold died from prostate cancers**⁶
- **A multi-modal threshold**, below which no benefit for treatment beyond surgery alone or radiation therapy alone was shown^{10,11} and an estimate of 10-yr metastasis risk reduction when androgen deprivation therapy is added to radiation therapy is reported.^{12,13}
- Test reports are **easy to follow and share with patients**, improving confidence in decision making



Scan the QR code for information about Prolaris + AI Test results, evidence, and AI technology



Combining germline and somatic testing reveals more in advanced prostate cancer care

MyRisk®
Hereditary Cancer Test

Precise Tumor®
Molecular Profile Test

Patients with advanced prostate cancer may qualify for immunotherapy and targeted therapies such as PARP inhibitors based on their germline and somatic mutation status.¹⁴

Germline testing

for all patients with high-risk, very high-risk, regional, or metastatic prostate cancer (or any stage with family history suggestive of hereditary cancer).¹⁴



Somatic tumor testing

for metastatic prostate cancer to detect DNA repair gene mutations (e.g., *BRCA1*, *BRCA2*, *ATM*, etc.), relevant for PARP inhibitor eligibility and other targeted therapies.¹⁴

Combining both tests doubles the chances of identifying clinically actionable mutations.¹⁵

The MyRisk® Hereditary Cancer Test is a guideline-driven germline test that evaluates clinically actionable genes and helps healthcare providers personalize care plans.

- Determines eligibility for targeted therapies such as PARP inhibitors^{14,16}
- Delivers the industry's lowest reported rates of variants of uncertain significance (VUS) for *BRCA1* (0.3%) and *BRCA2* (0.7%)¹⁷

The Precise Tumor® Molecular Profile Test is a somatic test that analyzes over 500 genes, as well as key biomarkers with broad coverage of guidelines.¹⁸

- Determines eligibility for FDA-approved therapies and clinical trials
- Includes DNA, RNA, and immuno-oncology biomarkers such as MSI, TMB, and PD-L1 (optional) for more actionable findings

Why choose Myriad for prostate cancer care?



State-of-the-art facilities

One of the world's most advanced genome centers and industry-leading turnaround time.



Comprehensive testing

Complete portfolio of genetic testing with one trusted lab.



Affordable

Myriad promises affordable access to testing for all patients and their families.



Advancing patient care through collaboration and research

The Myriad Collaborative Research Registry™ (MCRR) is one of the largest pan-cancer registries (>1.1M patients) of de-identified genetic, genomic, and clinical data freely available for research and data exploration.

EACH STEP. EVERY PATIENT. EXACTLY WHAT YOU NEED.



LEARN MORE

myriad.com/urology

Germline

MyRisk®

Hereditary Cancer Test

Tumor Genomic

Precise Tumor®

Molecular Profile Test

Prolaris®+ AI

Prostate Cancer Prognostic Test

1. Data on File at Myriad Genetics, Inc. Based on a review of 12 months of past claim data for major insurance carriers across the US, the majority of patients face no out-of-pocket costs for their MyRisk test. Last updated 2024. **2.** Data on File at Myriad Genetics, Inc. Based on a review of 12 months of past claim data for major insurance carriers across the US, the majority of patients face no out-of-pocket costs for their Prolaris test. Last updated 2024. **3.** Cuzick J, et al. *Lancet Oncol.* 2011;12(3):245-255. **4.** Cuzick J, et al. *Br J Cancer.* 2012;106(6):1095-1099. **5.** Cuzick J, et al. *Br J Cancer.* 2015;113(3):382-389. **6.** Lin DW, et al. *Urol Oncol.* 2018;36(6):310.e7-310.e13. **7.** Monda SM, et al. Poster session presented at: ASCO-GU; 2026 Feb; San Francisco, CA. **8.** Mabey B, et al. medRxiv. 2026; [Preprint] doi: <https://doi.org/10.64898/2026.05.15.26353328>. **9.** Hu JC, et al. *JCO Precis Oncol.* 2018;2:P0.18.00163. **10.** Tward JD, et al. *Clin Genitourin Cancer.* 2021;19(4):296-304.e3. **11.** Tward JD, et al. *Int J Radiat Oncol Biol Phys.* 2022;113(1):66-76. **12.** Tward JD, et al. *JCO Precis Oncol.* 2024 May;8:e2300722. **13.** Kishan AU, et al. *Lancet Oncol.* 23:304-316 (2022) **14.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer. V5.2026. ©National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 17, 2026. To view the most recent and complete version of the guideline, visit NCCN.org. **15.** Berchuck JE, et al. *JCO Precis Oncol.* 2022;6:e2200329. **16.** National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V3.2026. ©National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 17, 2026. To view the most recent and complete version of the guideline, visit NCCN.org. **17.** Mundt E, et al. Myriad's Multidisciplinary Approach and Consistent Investment in Variant Classification for Clinical Decision Making [White paper]. Myriad Genetics. 2025. **18.** Conroy JM, et al. *PLoS One.* 2021;16(12):e0260089. // NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Myriad
Oncology™

prolaris.com / Myriad Genetics / 322 North 2200 West, Salt Lake City, UT 84116

©2026 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, Prolaris, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. OPFCPUROBRO 0526